← All trials
NCT05017311
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Aug 23, 2021
- Last posted
- Sep 5, 2021
- Enrollment
- 400
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- Unity Health TorontoCollaborator
- McGill UniversityCollaborator
- McMaster UniversityCollaborator
- Queen's University, BelfastCollaborator
- Simon Fraser UniversityCollaborator
- University of MichiganCollaborator
- University of OttawaCollaborator
- University of TorontoCollaborator
- University of TorontoCollaborator
- University of TorontoOverall official - principal investigator
- University of TorontoReponsible party - principal investigator
- Dalhousie UniversityCollaborator
- University of British ColumbiaCollaborator
- University of CalgaryCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.